These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 15475317)
21. When more isn't merrier: pharmaceutical alliance networks and breakthrough innovation. Dong JQ; McCarthy KJ Drug Discov Today; 2019 Mar; 24(3):673-677. PubMed ID: 30639556 [TBL] [Abstract][Full Text] [Related]
22. Drug discovery: new models for industry-academic partnerships. Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364 [TBL] [Abstract][Full Text] [Related]
23. Conflict of interest or productive collaboration? The pharma: academic relationship and its implications for headache medicine. Finkel AG Headache; 2006; 46(7):1181-5. PubMed ID: 16866722 [No Abstract] [Full Text] [Related]
28. Crowdsourcing in pharma: a strategic framework. Bentzien J; Bharadwaj R; Thompson DC Drug Discov Today; 2015 Jul; 20(7):874-83. PubMed ID: 25637169 [TBL] [Abstract][Full Text] [Related]
29. Looking outward: content as a service starts to make sense. Sherlock A Drug Discov Today; 2013 Jan; 18(1-2):1-3. PubMed ID: 23041498 [No Abstract] [Full Text] [Related]
30. The road ahead for large pharma: long-term science and innovation. Lundberg JM; Reilly C Drug Discov Today; 2009 May; 14(9-10):439-41. PubMed ID: 19429501 [No Abstract] [Full Text] [Related]
31. The paradox of scientific excellence and the search for productivity in pharmaceutical research and development. Grasela TH; Slusser R Clin Pharmacol Ther; 2014 May; 95(5):521-7. PubMed ID: 24458012 [TBL] [Abstract][Full Text] [Related]
33. Open-minded to open innovation and precompetitive collaboration. Wagner JA Clin Pharmacol Ther; 2010 May; 87(5):511-5. PubMed ID: 20407451 [No Abstract] [Full Text] [Related]
34. Transforming the work of early-stage drug discovery through bioprocess informatics. Holzman TF; Hebert EJ Drug Discov Today; 2005 Jan; 10(1):61-7. PubMed ID: 15676300 [TBL] [Abstract][Full Text] [Related]
35. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration. Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460 [TBL] [Abstract][Full Text] [Related]
36. The strategic relevance of manufacturing technology: An overall quality concept to promote innovation preventing drug shortage. Panzitta M; Ponti M; Bruno G; Cois G; D'Arpino A; Minghetti P; Mendicino FR; Perioli L; Ricci M Int J Pharm; 2017 Jan; 516(1-2):144-157. PubMed ID: 27838294 [TBL] [Abstract][Full Text] [Related]
37. Open innovation: share or die.. Talaga P Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629 [No Abstract] [Full Text] [Related]
38. The pharmaceutical industry at risk: how excessive government regulation stifles innovation. Epstein RA Clin Pharmacol Ther; 2007 Aug; 82(2):131-2. PubMed ID: 17632536 [TBL] [Abstract][Full Text] [Related]
39. A novel pharmaceutical-ACO collaboration: the Merck/Heritage Provider Network open innovation challenge. Bhandari A; Chatterjee A; Holoubek S; Powers B; Gluck J; Jain SH Am J Manag Care; 2014 Jul; 20(10 Spec No):E4. PubMed ID: 25549555 [No Abstract] [Full Text] [Related]
40. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008. Shumoogam J; Al-Shamahi A IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]